Journal
CANCER CELL
Volume 36, Issue 1, Pages 1-3Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2019.06.001
Keywords
-
Categories
Funding
- Fondazione AIRC, Associazione Italiana per la Ricerca sul Cancro [18532]
- AIRC [21091]
- AIRC/CRUK/FC AECC Accelerator Award [22795]
- Transcan, TACTIC
- European Union H2020 COLOSSUS
- Fondazione Piemontese per la Ricerca sul Cancro-ONLUS, 5x1000 Ministero della Salute
Ask authors/readers for more resources
In this issue of Cancer Cell, Woolston et al. show that colorectal cancers that become refractory to initially effective anti-EGFR therapy contain an abundance of stromal and immune cells, irrespective of the contextual presence of resistance-conferring mutations. This reconfiguration puts forward therapeutic opportunities for patients who relapse on EGFR-targeting treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available